MannKind Corporation Receives 'Buy' Rating from H.C. Wainwright Amid Strong Growth and Promising Product Pipeline

H.C. Wainwright maintains a 'Buy' rating for MannKind Corp (MNKD) with a $9 price target. The rating is based on the company's strong growth, Tyvaso DPI, and product pipeline, including MNKD-101 and MNKD-201. The firm expects Afrezza to generate $127 million in sales by 2030.

July 2, 2025

In a significant move, H.C. Wainwright & Co. has assumed coverage of MannKind Corporation (NASDAQ: MNKD) with a 'Buy' rating and a $9 price target. The research firm's bullish stance is underpinned by the company's impressive 32.5% growth over the past 12 months and its robust product pipeline, including Tyvaso DPI and MNKD-101 and MNKD-201. According to H.C. Wainwright, Tyvaso DPI is expected to be a key driver of MannKind's valuation in the near future, while the Afrezza product line is forecasted to generate $127 million in sales by 2030 [1].

MannKind Corporation, based in Danbury, Connecticut, develops and commercializes inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases. Its primary product, Afrezza, is an inhaled ultra-rapid-acting insulin for diabetes. The company's strong growth and promising pipeline have caught the attention of H.C. Wainwright, who anticipates a 40% and 30% probability of success for MNKD-101 and MNKD-201, respectively [1].

While the 'Buy' rating and price target reflect MannKind's potential, H.C. Wainwright acknowledges that certain AI stocks may offer greater upside potential with less downside risk. For investors seeking undervalued AI stocks that could benefit from Trump-era tariffs and the onshoring trend, H.C. Wainwright suggests checking out their free report on the best short-term AI stock [1].

References:
[1] https://ca.finance.yahoo.com/news/h-c-wainwright-affirms-mannkind-104656188.html